Fernández-Ruiz J - Search Results

1

VCE-003.2, a novel cannabigerol derivative, enhances neuronal progenitor cell survival and alleviates symptomatology in murine models of Huntington's disease.

Díaz-Alonso J, Paraíso-Luna J, Navarrete C, Del Río C, Cantarero I, Palomares B, Aguareles J, Fernández-Ruiz J, Bellido ML, Pollastro F, Appendino G, Calzado MA, Galve-Roperh I, Muñoz E. Díaz-Alonso J, et al. Sci Rep. 2016 Jul 19;6:29789. doi: 10.1038/srep29789. Sci Rep. 2016. PMID: 27430371 Free PMC article.

2

Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease.

Lastres-Becker I, Molina-Holgado F, Ramos JA, Mechoulam R, Fernández-Ruiz J. Lastres-Becker I, et al. Neurobiol Dis. 2005 Jun-Jul;19(1-2):96-107. doi: 10.1016/j.nbd.2004.11.009. Neurobiol Dis. 2005. PMID: 15837565

3

Cannabinoids and neuroprotection in basal ganglia disorders.

Sagredo O, García-Arencibia M, de Lago E, Finetti S, Decio A, Fernández-Ruiz J. Sagredo O, et al. Mol Neurobiol. 2007 Aug;36(1):82-91. doi: 10.1007/s12035-007-0004-3. Epub 2007 Jun 23. Mol Neurobiol. 2007. PMID: 17952653 Review.

4

Cannabinoids and neuroprotection in motor-related disorders.

de Lago E, Fernández-Ruiz J. de Lago E, et al. CNS Neurol Disord Drug Targets. 2007 Dec;6(6):377-87. doi: 10.2174/187152707783399210. CNS Neurol Disord Drug Targets. 2007. PMID: 18220777 Review.

5

Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease.

Sagredo O, González S, Aroyo I, Pazos MR, Benito C, Lastres-Becker I, Romero JP, Tolón RM, Mechoulam R, Brouillet E, Romero J, Fernández-Ruiz J. Sagredo O, et al. Glia. 2009 Aug 15;57(11):1154-67. doi: 10.1002/glia.20838. Glia. 2009. PMID: 19115380 Free PMC article.

6

Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity.

Palazuelos J, Aguado T, Pazos MR, Julien B, Carrasco C, Resel E, Sagredo O, Benito C, Romero J, Azcoitia I, Fernández-Ruiz J, Guzmán M, Galve-Roperh I. Palazuelos J, et al. Brain. 2009 Nov;132(Pt 11):3152-64. doi: 10.1093/brain/awp239. Epub 2009 Oct 5. Brain. 2009. PMID: 19805493

7

Cannabinoids and Parkinson's disease.

García-Arencibia M, García C, Fernández-Ruiz J. García-Arencibia M, et al. CNS Neurol Disord Drug Targets. 2009 Dec;8(6):432-9. doi: 10.2174/187152709789824642. CNS Neurol Disord Drug Targets. 2009. PMID: 19839934 Review.

8

Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease.

Blázquez C, Chiarlone A, Sagredo O, Aguado T, Pazos MR, Resel E, Palazuelos J, Julien B, Salazar M, Börner C, Benito C, Carrasco C, Diez-Zaera M, Paoletti P, Díaz-Hernández M, Ruiz C, Sendtner M, Lucas JJ, de Yébenes JG, Marsicano G, Monory K, Lutz B, Romero J, Alberch J, Ginés S, Kraus J, Fernández-Ruiz J, Galve-Roperh I, Guzmán M. Blázquez C, et al. Brain. 2011 Jan;134(Pt 1):119-36. doi: 10.1093/brain/awq278. Epub 2010 Oct 7. Brain. 2011. PMID: 20929960

9

Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease.

Sagredo O, Pazos MR, Satta V, Ramos JA, Pertwee RG, Fernández-Ruiz J. Sagredo O, et al. J Neurosci Res. 2011 Sep;89(9):1509-18. doi: 10.1002/jnr.22682. Epub 2011 Jun 14. J Neurosci Res. 2011. PMID: 21674569

10

Cannabinoids: novel medicines for the treatment of Huntington's disease.

Sagredo O, Pazos MR, Valdeolivas S, Fernandez-Ruiz J. Sagredo O, et al. Recent Pat CNS Drug Discov. 2012 Apr 1;7(1):41-8. doi: 10.2174/157488912798842278. Recent Pat CNS Drug Discov. 2012. PMID: 22280340 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

417 results

Search Page